Genmab A (GMAB) Research & Development (2018 - 2026)

Genmab A (GMAB) has reported Research & Development for 9 consecutive years, with -$459.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 36.51% year-over-year to -$459.0 million; the trailing twelve-month figure through Jun 2026 stood at -$2.7 billion (up 23.41% YoY), and the FY2025 full-year result was -$1.6 billion, down 13.58% from the prior year.
• Research & Development eased to -$459.0 million in Q2 2026 per GMAB's latest filing, from -$440.0 million in the prior quarter.
• Across five years, Research & Development topped out at -$130.7 million in Q2 2022 and bottomed at -$2.1 billion in Q3 2023.
• Historically, Research & Development has averaged -$772.3 million across 5 years, with a median of -$696.0 million in 2024.
• The widest YoY moves for Research & Development: up 50.57% in 2024, down 294.92% in 2024.
• Over 5 years, Research & Development stood at -$130.7 million in 2022, then sank by 747.03% to -$1.1 billion in 2023, then retreated by 27.73% to -$1.4 billion in 2024, then grew by 23.62% to -$1.1 billion in 2025, then soared by 57.5% to -$459.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered -$459.0 million, -$440.0 million, and -$1.1 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.